Overview

• In the V‑DIFFERENCE trial, 85% of patients receiving inclisiran plus high‑intensity statin and tailored lipid‑lowering therapies met LDL‑C targets at 90 days versus 31% with placebo plus the same regimen.
• Patients on inclisiran were 43% less likely to report muscle‑related issues compared with those on placebo.
• The randomized study enrolled roughly 1,770 adults, assigning 898 to inclisiran and 872 to placebo on top of guideline‑directed cholesterol therapies.
• Inclisiran is an RNA‑targeting injection given initially, again at three months, then every six months to curb production of a protein that raises LDL cholesterol.
• Investigators describe this as the first inclisiran trial focused on patient outcomes, and broader peer review is pending once the full data are presented.